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Abstract
Idiopathic renal hypouricaemia is an inherited form of hypouricaemia, associated with abnormal renal handling of uric acid.
There is excessive urinary wasting of uric acid resulting in hypouricaemia. Patients may be asymptomatic, but the persistent
urinary abnormalities may manifest as renal stone disease, and hypouricaemia may manifest as exercise induced acute
kidney injury. Here we have identified Macedonian and British patients with hypouricaemia, who presented with a variety of
renal symptoms and signs including renal stone disease, hematuria, pyelonephritis and nephrocalcinosis. We have identified
heterozygous missense mutations in SLC22A12 encoding the urate transporter protein URAT1 and correlate these genetic
findings with functional characterization. Urate handling was determined using uptake experiments in HEK293 cells. This
data highlights the importance of the URAT1 renal urate transporter in determining serum urate concentrations and the
clinical phenotypes, including nephrolithiasis, that should prompt the clinician to suspect an inherited form of renal
hypouricaemia.
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Introduction
In man, the level of serum uric acid is determined primarily by
the production of urate, as an end product of purine metabolism
(for which the liver enzyme xanthine oxidase is necessary) versus
biliary and urinary tract elimination. In the majority of other
mammals, uric acid is metabolized by uricase (urate oxidase) to
allantoin, before urinary excretion. Thus man (and other species
lacking uricase, such as great apes), has comparably higher serum
uric acid levels than most mammals.
The renal handling of uric acid is a complex and incompletely
understood process [1,2]. Uric acid is freely filtered at the
glomerulus, the majority undergoes reabsorption via proximal
tubular urate transporter proteins and a proportion (,10%) is
secreted back into the filtrate in the late proximal tubule.
Molecular genetic and genome wide association studies have
recently allowed the identification of several proximal tubule urate
transporters including URAT1 (alias SLC22A12) [3] and GLUT9
(alias SLC2A9) [4,5,6]. Proposed models of urate transport in the
proximal tubule [7] suggest an initial uptake of uric acid from the
filtrate by URAT1, coupled to organic acid transporters. GLUT9,
in two different isoforms, allows for basolateral exit of urate from
the proximal tubule (isoform I) and regulation of urate entry/exit
at the apical membrane (GLUT9DN isoform). Finally, in the late
proximal tubule there are transporter proteins mediating uric acid
secretion (including ABCG2, NPT1 and NPT4) [7]. As uric acid
excretion is mediated through molecular transporters, certain
drugs such as fenofibrate, valproic acid, trimethoprim and losartan
may be used to manipulate these processes [8,9,10], thus allowing
manipulation of serum uric acid levels.
In humans, genetic defects in the activity of xanthine oxidase or
an acquired defect in liver enzyme function or renal uric acid
handling may result in hypouricaemia. Acquired hypouricaemia
may be seen in a number of clinical disorders, including Fanconi
syndrome [11], type 1 and type 2 diabetes mellitus [12,13],
thyrotoxicosis [14], pseudohypoparathyroidism type 1b [15],
pseudoaldosteronism due to licorice ingestion [16], distal renal
tubular acidosis [17,18], obstructive jaundice [19] and severe
acute respiratory syndrome [20].
Idiopathic renal hypouricaemia is an inherited form of
hypouricaemia that is characterized by excessive urinary wasting
of uric acid leading to an increased clearance (and increased
fractional excretion) of uric acid. The majority of patients are
asymptomatic, but some may present with uric acid nephrolithiasis
or acute kidney injury following severe exercise [21]. In 2002,
Enomoto et al. reported that mutations in gene SLC22A12
encoding the URAT1 transporter were responsible for most cases
of idiopathic renal hypouricaemia [3]. Recently Anzai et al. found
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renal hypouricaemia [22]. It is noteworthy that reports of
idiopathic renal hypouricaemia secondary to mutations in uric
acid transporters URAT1 and GLUT9 were initially reported
from Japan, Korea and China [23]. More recently, three Jewish
Israeli families of Iraqi origin have been reported to have renal
hypouricaemia, with a common mutation in SLC22A12 [24].
Inactivating mutations in SLC22A12 have not yet, to our
knowledge, been reported in a Caucasian population.
The typical presentation of idiopathic renal hypouricaemia is
that of exercise induced acute kidney injury with a preceding
history of loin pain with nausea and vomiting for several hours
after physical exercise. The exact mechanism of renal damage is
unclear, but may relate to damage from oxygen free radicals [21].
In contrast to this dramatic presentation, most patients are well
with no overt clinical symptoms, although renal stones and
hematuria may be presenting symptoms and signs.
Here we present data from Skopje (Macedonia) and Newcastle
upon Tyne (UK) where we have investigated the underlying
genetic cause of hypouricaemia in patients of European descent.
We present mutations in SLC22A12 encoding URAT1 alongside
their clinical, biochemical and functional characterization. This
data highlights the importance of renal urate transporters in
determining serum urate concentrations, and the clinical pheno-
types that should lead the renal clinician to suspect an inherited
form of renal hypouricaemia.
Results
Clinical descriptions
A total of thirty two patients with hypouricaemia were recruited
(Macedonia, n=20 and United Kingdom n=12) for mutational
analysis of the SLC22A12 and SLC2A9 genes. The basic
demographic, clinical, laboratory and molecular genetic data
from these patients are given in Table 1. We found changes in
SLC22A12 in five patients from Macedonia and two patients from
the United Kingdom (Figure 1A). No pathogenic mutations in
SLC2A9 were identified. An outline of the clinical, biochemical
and molecular genetic features of each case is given below.
Patient SK-1: This 7 year old girl was referred to the
nephrology unit with persistent vomiting, presumed to be
secondary to a non-obstructive kidney stone. She had a history
of similar episodes during the preceding 6 months. On admission
she was alert, but pale and moderately dehydrated. Clinical
examination revealed that her abdomen was non-tender with no
renal masses. A renal ultrasound scan (USS) revealed a single stone
within the right kidney measuring 10 mm, without calyceal
dilatation. Laboratory investigations on admission revealed
normal renal function (serum creatinine 26 mmol/l, estimated
glomerular filtration rate 123 ml/min/1.73 m
2 (according to
Schwartz formula)). Although she was moderately dehydrated,
she had persistently low serum uric acid levels ranging from 0.72–
1.18 mg/dl. FEurate was elevated at 20.8%. Liver function tests,
serum electrolytes, total protein and albumin were within
reference values. Urinary excretion of cystine, calcium, phosphate,
oxalate, glucose, low molecular weight proteins, amino acids and
organic acids were also within reference limits. In order to clarify
the etiology of urolithiasis, urinary excretion of xanthine and
hypoxanthine was measured, showing normal values. Mutation
analysis of SLC22A12 revealed a heterozygous missense mutation,
leading to amino acid change p.R434C. Genetic screening of
other family members revealed that her brother and father both
carried the identical heterozygous change, but were asymptomatic
in terms of renal stones, with normal renal ultrasound scan and no
reported episodes of exercise induced renal failure. Biochemical
evaluation revealed that the father had normal values of serum
uric acid while the brother had moderately decreased serum uric
acid level (1.56 mg/dl).
Patient SK-2: This 18 year female was referred for management
of hypertension. She had a past medical history of pyelonephritis
and bilateral ureteric reflux with scarring of the left kidney, as
determined by USS and Tc
99DMSA scan. Laboratory investiga-
tions revealed serum creatinine and urea within normal limits. She
was found to have low serum uric acid levels on two occasions
(1.74 mg/dl and 1.78 mg/dl, respectively) with an increased
FEurate. She had mild proteinuria (0.35 g/24 h) and a renal USS
revealed a small left kidney, but no evidence of nephrolithiasis.
Mutational analysis of the SLC22A12 gene was performed and a
heterozygous missense mutation p.R434H was detected.
Patient SK-3: This 5 year old girl was admitted to the
nephrology unit with severe dehydration, polyuria and vomiting.
She was noted to have faltering growth and rickets. Laboratory
investigations revealed a hyperchloremic metabolic acidosis
(pH 7.23, HCO3 13.6 mmol/l, BE 212.6 mmol/l), hypokalemia
(3.0 mmol/l), hypophosphatemia (0.84 mmol/l) and hypouricae-
mia (1.24 mg/dl). Simultaneous measurement of urine pH with
electrode revealed value of 6.77 which pointed to distal
acidification defect (expected urine pH,5.5). There was evidence
of proteinuria on urine dipstix testing (1+) which was characterized
with SDS-PAG electrophoresis as complete tubular proteinuria.
There was a generalized hyperaminoaciduria, but no glucosuria.
There was also evidence of uricosuria (FEurate varied between 24–
Table 1. Demographic, clinical, biochemical and molecular genetic data on 6 patients with renal hypouricaemia.
Patient Age (yrs) Sex
Serum Urate
(mg/dl) FEurate (%) Renal symptoms* Comorbidity
URAT1 mutation
leading to missense
SK-1 7 F 0.72 21 Nephrolithiasis Cyclic vomiting p.R434C
SK-2 18 F 1.75 27 Previous pyelonephritis Reflux nephropathy; Hypertension p.R434H
SK-3 5.5 F 1.24 31 Nephrocalcinosis Distal renal tubular acidosis p.R434C
SK-4 8 M 1.24 27 Recurrent episodes of gross
hematuria and renal colic
Alport syndrome p.R347S
SK-5 7 F 1.28 17 None Hashimoto thyroiditis; vitiligo p.R434H
NC-1 41 F 2.00 (transient) 16 Recurrent nephrolithiasis Type I diabetes mellitus; hypothyroidism p.V388M
NC-2 45 F 2.02 N/A Recurrent nephrolithiasis None p.I75T
*Symptoms due to renal hypouricaemia, SK-Skopje, NC-Newcastle, FEurate- Fractional excretion of uric acid, N/A- not available.
doi:10.1371/journal.pone.0028641.t001
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Ultrasound examination revealed bilateral nephrocalcinosis and a
solitary cyst in the left kidney measuring 10 mm. Following alkali
therapy, metabolic compensation was achieved and her growth
pattern improved. Following correction of the metabolic acidosis,
the proximal defects of aminoaciduria and low molecular
proteinuria resolved. Serum electrolytes also normalized, but
there was persistent hypouricaemia during the two year observa-
tional period (1.24–1.36 mg/dl). Since the hypouricaemia was
associated with an elevated FEurate, we undertook mutational
analysis of SLC22A12 which revealed a heterozygous missense
mutation, leading to amino acid change R434C. The mother of
patient SK-3 (R434C) was also heterozygous for the R434C
variant in SLC22A12. Biochemical evaluation confirmed she had a
low normal serum uric acid level (2.3 mg/dl) with fractional
excretion of urate of 19.3%. She had a normal renal ultrasound,
but a past medical history of renal colic and passage of a single
calculus 10 years ago.
Patient SK-4: This 8 year old boy presented with recurrent
attacks of visible hematuria and sensorineural hearing loss. A
percutaneous renal biopsy was performed which demonstrated
minimal glomerular abnormalities on light microscopy. Immuno-
fluorescence studies did not reveal any immune deposits and
electron microscopic analysis was not available. Given a clinical
suspicion of Alport syndrome, genetic studies were performed,
identifying a mutation in the COL4A5 gene. Following another
attack of visible hematuria with very severe colicky pain, serum
biochemistry revealed a low uric acid level. Repeated examina-
tions of the uric acid confirmed persistent hypouricaemia, with
high FEurate. Mutational analysis of SLC22A12 revealed a
heterozygous missense mutation, leading to the amino acid change
R347S. Genetic analysis confirmed that the mother of patient SK-
4 was also heterozygous for the sequence variant R347S.
Patient SK-5: A 7 year old female presented with vitiligo,
prompting a screen for autoimmune diseases. She was found to
have compensated hypothyroidism, with typical ultrasound
changes of the thyroid gland and increased antithyroid antibodies,
suggesting Hashimoto thyroiditis. She was also found to have
hypouricaemia with significant hyperuricosuria. She underwent
mutation analysis of SLC22A12 which revealed a heterozygous
missense mutation, p.R434H.
PatientNC-1: A 41 year oldfemalepresented with recurrent renal
colic, with 2 episodes in less than 12 months. She received lithotripsy
treatment for a left renal calculus (struvite stone). Her past medical
history was noteworthy for type 1 diabetes mellitus, since 10 years of
age, complicated by peripheral neuropathy and urinary tract
infections. She also had treated hypothyroidism. At presentation,
serum electrolyte abnormalities revealed a borderline low uric acid
level and a serum creatinine of 95 mmol/L. A FEurate was transiently
raised at 16%. Repeat serum biochemistry revealed a serum uric
acid level of 3.86 mg/dl and a normalised FEurate.F o l l o w i n g
successful lithotripsy she has remained stone free for 5 years,
following advice regarding increased fluid intake. Genetic analysis of
SLC22A12 revealed a heterozygous missense mutation, p.V388M.
Patient NC-2: A 45 year old lady presented to the regional
lithotripsy unit for treatment. She had recurrent renal stone
disease (calcium oxalate) for 7 years, requiring both lithotripsy and
a right pyeloplasty. She was on no medications. Serum electrolytes
revealed a normal serum creatinine (75 mmol/l) with a low serum
uric acid (2.01mg/dl). FEurate was not available for this patient. We
performed genetic analysis of SLC22A12, which revealed a
heterozygous missense mutation, p.I75T.
In silico analysis of mutations
Following the identification of variants within the SLC22A12
gene encoding URAT1 (Figure 1A,B) we used online databases
Figure 1. Identification of mutations within SLC22A12 encoding URAT1. A. Chromatograms showing sequence data and translated amino
acids. These demonstrate heterozygous missense variants (above, arrowed) and normal controls (below). B. SLC22A12 encodes URAT1, a 553 amino
acid protein with a predicted 12 Transmembrane domains (TMPred). It has an intracellular N- and C- terminus. Amino acid residues implicated in
hypouricaemia and modelled in the present study are highlighted in red and include Isoleucine, I at position 75, arginine, R at position 347, Valine V
at position 388 and Arginine, R at position 434.
doi:10.1371/journal.pone.0028641.g001
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pathogenicity of each variant. Within the URAT1 amino acid
sequence, residues R347, V388 and R434 are highly conserved,
whilst I75 is not well conserved (Table 2). SIFT and Snps3d
analysis predicted all 5 sequence variants to be either not tolerated
(SIFT) or deleterious (Snps3D). Polyphen analysis predicted that 3
out of the 5 missense changes to be ‘‘probably damaging’’, with
V388M and I75T predicted to be benign (Table 2).
Functional studies of URAT1 variants
Using mammalian cells, we evaluated the urate transport
function of URAT1 sequence variants found in this study. Urate
uptake was measured in transiently transfected HEK293 cells,
comparing wild-type transporter activity to sequence variants
I75T, R347S, R434C and R434H.
Following transient transfection of HEK293 cells with FLAG-
tagged URAT1 constructs, we demonstrate strong plasma
membrane expression in wild-type URAT1 (Figure 2A).
Plasma membrane expression levels of variants R434C and
R434H were low whereas the intracellular localization was not
strongly observed, possibly due to the stability of protein. For
variant I75T the partial membrane expression was observed
together with partial intracellular localization. For variants R347S
and V388M strong plasma membrane expression, similar to wild-
type levels was observed (Figure 2A).
Measurement of urate uptake in HEK293 cells demonstrates a
significant reduction of urate transport function by I75T, R347S,
R434C and R434H variants of URAT1 but not in V388M variant
(Figure 2B).
Discussion
Idiopathic renal hypouricaemia is a disorder that has been
characterized previously in patients from Far Eastern countries
including Japan, Korea and China. The disease may be completely
asymptomatic [23,25,26], but there are many reports, particularly
from Japan, where patients present with acute kidney injury
following strenuousphysical activities [21,27,28,29,30,31,32,33,34].
The exact mechanism of acute kidney injury remains elusive, but it
is believed that uric acid serves as an antioxidant, and in states of
hypouricaemia this protective role is lost. Kaneko et al. demon-
strated in a 15 year old girl with idiopathic renal hypouricaemia an
oxidative imbalance soon after exercise with a predisposition to
exercise-induced acute renal failure [35]. In contrast, some patients
may present with more minor renal features including nephrolithi-
asis or hematuria [23,31,36].
In 2002, Enomoto et al. established that URAT1 transporter
was responsible for tubular reabsorption of urate [3]. SLC22A12
encodes the protein URAT1 and loss of function mutations are
responsible for majority of patients with idiopathic renal
hypouricaemia. The W258X variant of URAT1 is a typical
mutation found in Japanese and Korean populations
[23,31,37,38]. Allele frequency of W258X in the general
population in Japan was found to be as high as 1.9% [39].
Heterozygous carriers of URAT1 mutations are usually asymp-
tomatic but they may develop nephrolithiasis. Prevalence of
hypouricaemia in Japan varies between 0.15% [40] and 0.23%
from the analysis of serum urate levels in 1730 school children
[41]. In Korea, the prevalence of hypouricaemia in healthy adults
is 3.3% [42]. Therefore, school-age children who plan to
performing competitive sporting activities are advised to have
their serum uric acid level checked [43].
Loss of function mutations affecting URAT1 have not been
previously reported in a Caucasian population. However, single
case reports from European patients presenting with clinical and
biochemical features of hereditary renal hypouricaemia exist
[44,45,46,47]. Tzovaras et al. tested nine Greek subjects with
primary renal hypouricaemia [48]. All had serum uric acid levels
,2.5 mg/dl, associated with a FEurate.10% and no other known
cause of hypouricaemia. No definite pathogenic mutations were
detected in this series and just one silent polymorphism
(1246T.C) in exon 2 of the SLC22A12 gene was noted. It is
questionable why hereditary renal hypouricaemia is apparently so
rare in Caucasian populations. Either the prevalence of URAT1
mutations is indeed low in this population, or a decreased
awareness of this disease and its presentation outside of the Far
East allows cases to go undetected. Even in Japan, there are
patients who have clinical features of renal hypouricaemia but no
SLC22A12 mutations. Very recently, a genome-wide association
study was performed in 6890 African Americans and 21708
European participants in order to try and identify risk alleles for
elevated serum urate, associated with gout [49]. A novel URAT1
variant (G65W) was identified (rs12800450) and was associated
with a reduction in serum urate of around 1.2 mg/dl per copy of
the minor allele. Urate transport studies demonstrated a reduction
in the urate transport for the G65W URAT1 variant [49]. This
study validates heterozygous changes within URAT1 as a
determinate of reduced serum urate levels. In this study the
variant allele provided a protective affect against gout, but one
may postulate that this may also be an at-risk allele for the
hypouricaemia. Both biochemically and clinically, a single
heterozygous change in URAT1 may be significant. Cheong et
Table 2. URAT1 variants and their in silico analysis for conservation and pathogenicity.
Missense change
in URAT1 Evolutionary conservation
SNP ID (Average
Hetrozygosity Index) SIFT analysis
Snps3d
analysis PolyPhen-2 analysis
I75T Not conserved between human,
mouse and zebrafish
rs141570522 (0.001) Predict Not
Tolerated
Deleterious Predicted to be benign
R347S Conserved Human to Mouse Novel variant Predict Not
Tolerated
Deleterious Predicted to be probably
damaging
V388M Conserved between human,
mouse and zebrafish
rs146388519 (0.000) Predict Not
Tolerated
Deleterious Predicted to be benign
R434C Conserved between human,
mouse and zebrafish
rs145200251 (0.001) Predict Not
Tolerated
Deleterious Predicted to be probably
damaging
R434H Conserved between human,
mouse and zebrafish
rs147647315 (0.011) Predict Not
Tolerated
Deleterious Predicted to be probably
damaging
doi:10.1371/journal.pone.0028641.t002
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whose mother and brother were also heterozygous for W258X and
had mild hypouricaemia and abnormally high FEurate, whilst his
father who was also heterozygous for W258X, had a normal serum
uric acid level of 4.6 mg/dL [23]. In the same report, an 11-year-
old girl with asymptomatic microscopic hematuria and low serum
urate was a compound heterozygote for W258X/R477H. Her
mother had a heterozygous W258X mutation associated with
renal hypouricaemia (serum uric acid 2.3 mg/dl and FEurate
16.3%) [23]. In addition, a 15 year old girl with haematuria,
proteinuria and renal hypouricaemia (serum uric acid 1.3 mg/dl
and FEurate 14.5%) was noted to have a single heterozygous
W258X mutation, whilst a 36-year-old female, with recurrent
episodes of uric acid stones in the right ureter had a serum uric
acid of 1.8 mg/dL and an elevated FEurate of 28.1%. She was
heterozygote for a R90H variant in URAT1 [23]. Va ´zquez-
Mellado et al. reported patients heterozygous for C850G in
URAT1 with primary gout and low serum uric acid concentra-
tions [50] whilst Ichida, et al. reported 5 individuals with a
W258X heterozygous change, one of whom had a history of acute
kidney injury and renal stones [23,31,36].
Recently, the GLUT9 glucose transporter, encoded by SLC2A9
gene has been shown to have an important functional role in
transporting uric acid from the renal tubular cells through the
basolateral membrane into interstitium [22]. Two additional
reports have confirmed this finding [51,52]. Matsuo et al. detected
two heterozygous mutations in GLUT9 in two hypouricaemic
subjects whom were negative for URAT1 mutations (R380W in
exon 10 and R198C in exon 6) and confirmed their reduced
transport activity in Xenopus oocyte expression system [51] whilst
Dinour et al. recently described two families with recessively
inherited hypouricaemia who were negative for URAT1 muta-
tions [52]. Among hypouricaemic subjects in both families, three
subjects had nephrolithiasis and three subjects had a history of
exercise induced acute kidney injury. With genome wide
homozygosity screen and linkage analyses they established SLC2A9
as a causative gene for renal hypouricaemia in these families. In
these families, homozygous carriers of SLC2A9 mutations had very
low serum levels of uric acid and extremely high values of FEurate
(at around 150%).
In this report we present combined data from Macedonian and
English patients who are heterozygous carriers of SLC22A12
sequence variants. Although the presentations of the patients were
varied, a systematic search for hypouricaemia identified patients
with possible hereditary renal hypouricaemia and who are suitable
for mutational analysis of SLC22A12 and SLC2A9 genes to try and
Figure 2. Functional analysis of changes in URAT1 expressed in HEK293 cells. A. HEK293 cells were transiently transfected with Flag-tagged
URAT1 cDNA constructs (wild-type and variants I75T, R347S, V388M, R434C and R434H). Plasma membrane expression was detected using an anti-
FLAG monoclonal antibody, secondarily detected using an Alexa FluorH 488 (green) antibody. Nuclei are counter stained using DAPI (blue). B. Uric
acid uptake by HEK293 cells transiently transfected with wild-type URAT1 or its mutants was measured using [
14C]Urate at 2 min, at 37uC and pH7.4.
Significant reductions in urate transport activity was seen in some of the disease-associated variants. Data are mean 6 S.E.M with n=4. ***, P,0.001
when compared with wild type.
doi:10.1371/journal.pone.0028641.g002
URAT1 Variants
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and GLUT9, respectively. We identified seven patients harboring
five SLC22A12 variants. Interestingly, three Macedonian patients
carried mutations at amino acid position 434 of URAT1.
Some of these variants in SLC22A12 were discovered following
significant clinical episodes including nephrolithiasis in patients
SK-1, NC-1 and NC-2. There were however, no episodes of
exercise induced acute kidney injury that we are aware of.
The sequence variant R434H was identified in one of our
patients with hypouricaemia. This variant has a reported
heterozygosity index of 0.011 (Table 2), although this variant
was not detected in our normal control subjects. Additional studies
are required to demonstrate whether this variant is a common
cause of hypouricaemia.
Of note, in our cohort of patients, we found no novel sequence
variants in the GLUT9 transporter (SLC2A9), leaving a number of
patients with unexplained hypouricaemia. However, given the
complexity of proximal tubule urate handling, other urate
transporter protein variants may account for hypouricaemia in
the remaining patients.
In patient SK-1 nephrolithiasis was likely to be due to multiple
risk factors including renal wasting of urate, episodes of cyclic
vomiting leading to concentrated urine and hypocitraturia. In
patient SK-4, who also had a molecular genetic diagnosis of Alport
syndrome, attacks of gross hematuria were confusing due to
presence of colicky pain and eumorphic red blood cells (100%),
which are not usual features of Alport syndrome. In this patient,
we found the mutation p.R347S. Cheong et al. reported a similar
case to this, where a 14 year old girl who presented with acute
post-streptococcal glomerulonephritis [23]. Although her nephritis
had a favorable course, the microhematuria persisted more than
one year. On reevaluation this girl was found to have low serum
uric acid (1.3 mg/dl) with increased FEurate (14.5%) in favor of
idiopathic hypouricaemia. Mutational analysis in this patient
revealed heterozygous W258X mutation in SLC22A12.
Patient SK-2 has hypertension and moderate proteinuria due to
reflux nephropathy, presumably as a coincidental finding to the
functionally significant p.R434H variant. As hypertension in the
context of renal disease is often treated with ACE inhibitors or
angiotensin receptor antagonists, some caution is advisable. Both
losartan [8] and irbesartan [53] have an inhibitory action on
URAT1. Thus treatment with these agents has potential to have a
marked uricosuric effect in patients with homozygous URAT1
mutations.
Patient SK-3 had a complex phenotype of distal renal tubular
acidosis and renal hypouricaemia, associated with the p.R434C
mutation within URAT1. It is well known that hypouricaemia
may be associated with distal renal tubular acidosis at diagnosis
[17,18] as a part of transitory proximal tubular dysfunction. In
additional, pharmacological agents may also disrupt proximal
tubular handing of urate. In our case, hypouricaemia persisted for
more than 2 years despite a normalization of other proximal
tubular functions. Definitively, mutational analysis of SLC22A12
with a functionally significant change (p.R434C) explained the
persistent hypouricaemia in this patient.
Patient NC-1 was a recurrent calcium stone former, with a past
medical history of type 1 diabetes. Here, serum urate levels were
only borderline low and the FEurate was also only transiently raised
at 16%. The missense mutation p.V388M was associated with
negative functional data, with no significant change in urate
transport in HEK293 cell experiments. Inclusion of this case is
helpful as the negative functional data and the transient
hypouricaemia are consistent with this variant being benign.
The dataset derived from the V388M variant allow a comparison
to be made between it and the more functionally significant
variants, acting as another negative control. Given the hypouri-
caemia was transient in this case, we do not assume that this
sequence variant is causative. From our sequence variants of
URAT1, mutations with an impact upon uric acid handling (when
modeled in HEK293 cells) are associated with a persistent
hypouricaemia. Patient NC-2 was also a recurrent stone former,
with persistently low serum uric acid. The heterozygous missense
mutation, p.I75T was confirmed to be functionally significant in
HEK293 urate uptake studies.
In previously reported Japanese and Korean cases of idiopathic
renal hypouricaemia secondary to SLC22A12 mutations, the
majority of patients have been shown to have either homozygous
mutations or compound heterozygote mutations [23]. In our
Caucasian population, disease associations have been made with
single heterozygous changes in URAT1, suggesting that such a
change is sufficient and that a dominant pattern of inheritance
may be present.
In conclusion, we have identified Macedonian and British
patients with hypouricaemia, who presented with symptoms
including renal stone disease and haematuria. We have identified
missense mutations in SLC22A12 encoding URAT1. This data
highlights the importance of renal urate transporters in determin-
ing serum urate concentrations and the of clinical phenotypes that
should lead the clinician to suspect an inherited form of renal
hypouricaemia.
Materials and Methods
Ethics Statement
For Macedonia patients, the Institutional Review Board and the
Ethics Committee at the Medical Faculty and The Ministry of
Education and Science, Skopje, Republic of Macedonia approved
the study. Informed written consent was obtained by participants’
parents or legal guardians. For UK patients, full ethical approval
was obtained by the Newcastle and North Tyneside Research
Ethics Committee and informed written consent were obtained
from participants.
Recruitment of patients
Macedonian patients: Children attending in-patient or out-
patient nephrology service at the University Children’s Hospital,
Skopje were screened for hypouricaemia. Serum uric acid level
was determined in children with contraction or expansion of the
extracellular volume, acute kidney injury, chronic kidney disease,
nephrolithiasis, tubular disorders, those receiving diuretics or
nephrotoxic drugs, liver diseases, diabetes mellitus and thyroid
diseases. Children less than two years of age were excluded from
this study since they have physiologically lower levels of uric acid
due to immaturity of the liver and renal tubular function. Where
serum uric acid levels were ,2 mg/dl and Fractional Excretion of
urate (FEurate) was .10% (normal range 2–8%) and these
biochemical findings persisted despite clinical improvement and
normalization of other biochemical indices, or if no explanation
was found for lower serum levels of uric acid, than idiopathic renal
hypouricaemia was considered to be a likely diagnosis [23].
Patients with suspected renal hypouricaemia underwent additional
studies, including ultrasound imaging of the urinary tract (if
previously not performed) and molecular analysis of SLC22A12
and SLC2A9.
United Kingdom Patients: Adult kidney stone formers attending
for lithotripsy at the Newcastle upon Tyne NHS Foundation Trust
Hospital, UK were recruited (following informed consent) and
screened for serum and urinary biochemical abnormalities.
URAT1 Variants
PLoS ONE | www.plosone.org 6 December 2011 | Volume 6 | Issue 12 | e28641Twelve patients with hypouricaemia (,2.6 mg/dl) underwent
molecular analysis of SLC22A12 and SLC2A9.
Molecular analysis
Mutational analysis of SLC22A12 and SLC2A9 genes was
performed using exon PCR and direct sequencing. (Oligonucle-
otide primer sequences are listed in Table S1). For control patient
DNA screening, 92 samples were obtained from blood donor
(healthy control) panels.
In silico analysis of mutations
Online in silico analyses were performed when sequence
variants were identified. These included SIFT (http://sift.jcvi.
org/), PolyPhen (http://genetics.bwh.harvard.edu/cgi-bin/ggi/
ggi.cgi) and SNPS3D (www.snps3d.org/).
Functional expression studies
Full-length cDNA of human URAT1 was obtained as described
previously [3] and tagged with 36FLAG at the N-terminus. The
QuickChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla,
CA) was used to introduce point mutations into URAT1 cDNA in
the expression vector according to the instructions. Complemen-
tary oligonucleotides used for mutagenesis are described in Table
S2. All the final cDNA sequences were confirmed by DNA
sequencing.
For the evaluation of transport function of SLC22A12 mutations,
we used a mammalian cell expression system as described
previously [54]. Briefly, HEK293 cells [55] were maintained in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
10% fetal bovine serum (FBS), 1 mM sodium pyruvate, 100 U/ml
penicillin, and 100 mg/ml streptomycin (Invitrogen, Carlsbad,
CA) at 37uC and 5% CO2. Transient transfection with
Lipofectamine 2000 (Invitrogen) was performed according to the
manufacturer’s instructions. After transfection, the cells were
grown 36–48 h before the experiments.
Cellular uptake of [
14C]UA were measured in hURAT1 (or its
mutants)-transfected HEK293 cells [55] grown on poly-D-lysine-
coated 24-well plates. The cells were incubated in chloride-free
Hanks’ balanced salt solution (HBSS) containing the following in
mM: 125 Na gluconate, 4.8 K gluconate, 1.2 KH2PO4, 1.2
MgSO4, 1.3 Ca gluconate, 5.6 glucose and 25 HEPES, pH 7.4)
for 10 min. The uptake study was started by adding HBSS
containing [
14C]UA or to the plate. After 2 min, the cells were
washed three times in ice-cold HBSS, then lysed in 0.1 M NaOH
for 20 min followed by measurement of radioactivity by
scintillation counting. The experiments were performed in
quadruplicate per experiment and repeated twice. All the data
are given as the mean 6 S.D. The Student’s t-test was used to
determine significant differences. A value of P,0.05 was
considered to be significant.
Immunocytochemical analyses were performed as previously
described [56]. URAT1 (or its mutants)-transfected HEK293 cells
were fixed with methanol and incubated with the anti-FLAG
antibody (1:50) (Sigma) followed by Alexa FluorH 488-labelled
goat anti-rabbit immunoglobulin (Invitrogen; diluted 1:200). The
staining was observed under a confocal laser scanning microscope
(Fluoview FV1000, Olympus). Alexa 488 fluorescence was excited
by Argon laser light of wavelength 488 nm.
Supporting Information
Table S1 Oligonucleotide primers for exon PCR of SLC22A12
and SLC2A9.
(DOC)
Table S2 Oligonucleotide primer pairs used for site-directed
mutagenesis of SLC22A12.
(DOC)
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